New insomnia therapy for children: development of AI for therapy and proof-of-concept trial with Sheffield Children's NHS Foundation Trust
Lead Participant:
BRAINTRAIN2020 LIMITED
Abstract
The amount we sleep has been increasingly recognised as having an important impact on our health and well-being. Over recent years we have become increasingly aware of the effects that sleep has on both our physical and mental health. Even one bad night's sleep or late night can affect a person's mood, alertness and memory. The long-term effect of poor sleep can cause a range of life-threatening conditions such as cardiovascular disease, obesity and depression.
However, insomnia is a global epidemic affecting up to 25% of children and 35% of adolescents with 43% suffering with insomnia into adulthood (Fernandez-Mendoza, 2022).
Our mission is to rid the world of addictive sleeping tablets and provide a good night's sleep for everyone, improving health and well-being.
SleepCogni has identified an urgent clinical need for a solution to support children due to the current lack of treatment options. SleepCogni provides an innovative technological solution to this problem. The wearable medical device delivers sleep therapy offering immediate relief when it's needed most. The patented Active-Biofeedback technology delivers personalised therapy and provides unique behavioural insights to make meaningful improvements. This patented technology uses haptic feedback to break the cognitive cycles that prevent sleep. Providing sleep clinicians with an economical and efficient technological solution to manage insomnia.
SleepCogni now seek to develop and incorporate AI into our patented Active-Biofeedback therapy to improve the personalisation and engagement. Through our collaborators, Sheffield Children's NHS Foundation Trust, this will then be tested in children under 18 in a proof of concept trial to determine the efficacy and user experience.
SleepCogni will act as a first-line therapy solution which will directly address the growing waiting lists, helping paediatric patients self-manage their insomnia alongside their family.
However, insomnia is a global epidemic affecting up to 25% of children and 35% of adolescents with 43% suffering with insomnia into adulthood (Fernandez-Mendoza, 2022).
Our mission is to rid the world of addictive sleeping tablets and provide a good night's sleep for everyone, improving health and well-being.
SleepCogni has identified an urgent clinical need for a solution to support children due to the current lack of treatment options. SleepCogni provides an innovative technological solution to this problem. The wearable medical device delivers sleep therapy offering immediate relief when it's needed most. The patented Active-Biofeedback technology delivers personalised therapy and provides unique behavioural insights to make meaningful improvements. This patented technology uses haptic feedback to break the cognitive cycles that prevent sleep. Providing sleep clinicians with an economical and efficient technological solution to manage insomnia.
SleepCogni now seek to develop and incorporate AI into our patented Active-Biofeedback therapy to improve the personalisation and engagement. Through our collaborators, Sheffield Children's NHS Foundation Trust, this will then be tested in children under 18 in a proof of concept trial to determine the efficacy and user experience.
SleepCogni will act as a first-line therapy solution which will directly address the growing waiting lists, helping paediatric patients self-manage their insomnia alongside their family.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| BRAINTRAIN2020 LIMITED | £293,987 | £ 205,791 |
Participant |
||
| SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST | £47,476 | £ 47,476 |
People |
ORCID iD |
| Joseph Hawkins (Project Manager) |